Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIAID chemokine discovery may chart new course for HIV

This article was originally published in Scrip

Executive Summary

Like most stories of discovery, the unearthing by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) of a link between the protein CXCL4 and HIV suppression may still be far from a happy ending, in this case, potential translation into an effective treatment, preventive therapy or vaccine, explained Dr Paolo Lusso, chief of the viral pathogenesis section in the agency's Laboratory of Immunoregulation Scientists directed by NIAID chief Dr Anthony Fauci.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC017559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel